Pure Global AI
NCT06326658Not yet recruiting

Bufei Yishen Prescription on Patients With Frequent AECOPD in Stable Stage

Evaluation of the Curative Effect and Health Economics of Bufei Yishen Prescription on Patients With Frequent Acute Exacerbation of COPD in Stable Stage
Henan University of Traditional Chinese MedicineClinicalTrials.govother
Verified
Study focus
Disease/Condition
Chronic Obstructive Pulmonary Disease
Drug/Device/Intervention
Bufei Yishen Prescription Granule
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Henan University of Traditional Chinese Medicine
Timeline & enrollment
Phase
N/A
Start date
Apr 01, 2024
End date
Oct 31, 2026
Enrollment
848 participants
Primary outcome

The number of acute exacerbations

Summary

To evaluate the clinical efficacy and health economic advantages of Lung Replenishing and
 Kidney Enhancing Formula for the treatment of patients with frequent acute exacerbations in
 the stabilized phase.

ICD-10 classifications
Other chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease, unspecifiedOther specified chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease with acute exacerbation, unspecifiedChronic obstructive pulmonary disease with acute lower respiratory infection
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06326658
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06326658 through Pure Global AI's free database. This phase not specified trial is sponsored by Henan University of Traditional Chinese Medicine and is currently Not yet recruiting. The study focuses on Chronic Obstructive Pulmonary Disease. Target enrollment is 848 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.